BioCardia, Inc. announced on June 25, 2025, that the United States Patent Office has granted US Patent No. 12,311,127. The patent is titled 'Radial and Trans-endocardial Delivery Catheter'.
This new patent describes the company’s minimally invasive interventional catheter systems designed to deliver biologic therapies to target sites in the heart. This technology is a core component of BioCardia's therapeutic delivery platforms.
The addition of this patent strengthens BioCardia's intellectual property protection for its Helix biotherapeutic delivery system in the United States. This is significant for both the company's ongoing clinical trials and its strategy to partner with other biotherapeutic developers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.